Rhythm Pharmaceuticals Inc
RYTM
NASDAQ
Biotechnology
$115.48
USD
-0.54 (-0.47%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $8.14B
Volume 334.9K
Revenue
$239.92M
TTM
+53.5%
YoY
Gross Margin
89%
TTM
-0.3%
YoY
Net Income
$-205.35M
TTM
-12.2%
YoY
Operating Cash Flow
$-105.35M
TTM
+2.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 48.5 | 51.3 | 57.3 | 60.1 | 71.3 |
YoY Growth | +66.8% | +54.3% | +36.9% | +83.8% | +46.9% |
Cost of Revenue | 5.5 | 5.5 | 4.8 | 7.2 | 8.9 |
Gross Profit | 43.0 | 45.8 | 52.5 | 53.0 | 62.3 |
Selling, General & Administrative | 45.9 | 52.4 | 57.5 | 63.6 | 67.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 88.3 | 98.5 | 99.5 | 105.3 | 110.9 |
Operating Income | -45.3 | -52.7 | -47.1 | -52.4 | -48.6 |
EBITDA | -44.9 | -52.3 | -46.8 | -52.1 | -48.3 |
Other Income / Expense | 1.6 | 0.3 | 0.1 | -1.7 | 1.0 |
Total Other Income / Expense | -1.0 | -0.1 | -0.5 | -2.7 | -0.3 |
Income Before Income Taxes | -46.3 | -52.8 | -47.5 | -55.1 | -48.9 |
Income Taxes | 0.3 | 0.1 | -0.0 | 0.5 | 0.4 |
Net Income | -46.6 | -52.9 | -47.5 | -55.6 | -49.3 |
Consolidated Net Income / Loss | -46.6 | -52.9 | -47.5 | -55.6 | -49.3 |
Net Income Attributable to Common Shareholders | -48.0 | -54.3 | -48.8 | -56.7 | -50.4 |
Basic EPS | -$0.75 | -$0.82 | -$0.73 | -$0.83 | -$0.73 |
Diluted EPS | -$0.75 | -$0.82 | -$0.73 | -$0.83 | -$0.73 |
Basic Shares Outstanding | 63.7M | 66.3M | 66.9M | 68.0M | 68.6M |
Diluted Shares Outstanding | 63.7M | 66.3M | 66.9M | 68.0M | 68.6M |